Ropes & Gray represented Shanghai-based biotechnology LianBio in a strategic collaboration with Pfizer to develop and commercialize therapeutic products in Greater China. The transaction was announced on November 19.
In addition to Pfizer’s participation in LianBio’s recent crossover financing, under the terms of the collaboration, Pfizer will contribute up to $70 million of non-dilutive capital toward in-licensing and co-development.
At LianBio’s discretion, products will be presented to Pfizer for joint development. Pfizer will have a right of first negotiation to obtain commercial rights to jointly developed therapies and each will carry separate financial considerations. During the collaboration, Pfizer may provide in-kind support for marketing, development and regulatory activities.
The Ropes & Gray team was led by life sciences partner Eric Wu (Shanghai).
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.